Compliance of a cobalt chromium coronary stent alloy – the COVIS trial

Hagemeister, Jens; Baer, Frank M.; Schwinger, Robert H. G.; Höpp, Hans W.

doi:10.1186/1468-6708-6-17

Cited by 19 publications

(10 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Como outros atrativos, esse stent possui moderna plataforma de cobalto-cromo, de hastes muito finas, mas com boa radiopacidade, tendo demonstrado excelente navegabilidade em estudos pré-clínicos 13 .…”

Section: Discussionunclassified

Análise angiográfica e ultra-sonográfica do stent liberador de novolimus para o tratamento de lesões coronárias de novo: resultados do estudo EXCELLA I

Maia¹,

Abizaid²,

Costa³

et al. 2008

Rev. Bras. Cardiol. Invasiva

View full text Add to dashboard Cite

Section: Discussionunclassified

Análise angiográfica e ultra-sonográfica do stent liberador de novolimus para o tratamento de lesões coronárias de novo: resultados do estudo EXCELLA I

Maia¹,

Abizaid²,

Costa³

et al. 2008

Rev. Bras. Cardiol. Invasiva

View full text Add to dashboard Cite

“…The platform of the Xience V stent is a L-605 cobalt chromium (CoCr) balloon expandable stent remarkably similar to its successful BMS equivalent, the Multi-Link Vision ® (Abbott Laboratories), whose main characteristics are low strut thickness, high flexibility and deliverability, acceptable compliance, recoil and risk of plaque prolapse, and overall good radiopacity (Hagemeister et al 2005; Tanimoto et al 2007). The performance of the Multi-Link Vision has already been proved in clinical practice, and this stent is among the most commonly used worldwide (Kaiser et al 2005; Ortolani et al 2007; Xu et al 2007).…”

Section: Design and Pharmacology Of The Xience V Stent And Preclinicamentioning

confidence: 99%

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®)

Sheiban¹

2008

Vasc Health Risk Manag

View full text Add to dashboard Cite

Percutaneous coronary revascularization has been a mainstay in the management of coronary artery disease since its introduction in the late 1970s. Bare-metal stents and, more recently, first-generation drug-eluting stents (DES), such as sirolimus-eluting (Cypher®) and paclitaxel-eluting stents (Taxus®), have further improved results of percutaneous coronary intervention (PCI) by improving early results and reducing the risk of restenosis. There is currently debate on the safety of these first-generation DES, given the potential for late stent thrombosis, especially after discontinuation of dual antiplatelet therapy. There are well known caveats on the performance of their respective metallic stent platforms, delivery, and dilation systems, and polymer coatings. Second-generation DES, such as zotarolimus-eluting (Endeavor®) and everolimus-eluting stents (Xience V®), have recently become available in the USA and/or Europe. The Xience V stent holds the promise of superior anti-restenotic efficacy as well as long-term safety. In addition, this stent is based on the Multi-link platform and delivery system. Recently available data already suggest the superiority of the Xience V stent in comparison to the Taxus stent in terms of prevention of restenosis, without significant untoward events. Nonetheless, the number of patients studied and the follow-up duration are still too limited to enable definitive conclusions. Only indirect meta-analyses can be used to date to compare the Xience V with the Cypher. This systematic review tries to provide a concise and critical appraisal of the data in support of the Xience V everolimus-eluting stent.

show abstract

“…The platform of the Xience V stent is a L-605 cobalt chromium (CoCr) balloon expandable stent remarkably similar to its successful BMS equivalent, the Multi-Link Vision ® Xience V everolimus-eluting stent (Abbott Laboratories), whose main characteristics are low strut thickness, high fl exibility and deliverability, acceptable compliance, recoil and risk of plaque prolapse, and overall good radiopacity (Hagemeister et al 2005;Tanimoto et al 2007). The performance of the Multi-Link Vision has already been proved in clinical practice, and this stent is among the most commonly used worldwide (Kaiser et al 2005;Ortolani et al 2007;Xu et al 2007).…”

Section: Design and Pharmacology Of The Xience V Stent And Preclinicamentioning

confidence: 99%

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V<sup>®</sup>)

Biondi-Zoccai¹

2008

VHRM

View full text Add to dashboard Cite

Percutaneous coronary revascularization has been a mainstay in the management of coronary artery disease since its introduction in the late 1970s. Bare-metal stents and, more recently, fi rst-generation drug-eluting stents (DES), such as sirolimus-eluting (Cypher ® ) and paclitaxel-eluting stents (Taxus ® ), have further improved results of percutaneous coronary intervention (PCI) by improving early results and reducing the risk of restenosis. There is currently debate on the safety of these fi rst-generation DES, given the potential for late stent thrombosis, especially after discontinuation of dual antiplatelet therapy. There are well known caveats on the performance of their respective metallic stent platforms, delivery, and dilation systems, and polymer coatings. Second-generation DES, such as zotarolimus-eluting (Endeavor ® ) and everolimus-eluting stents (Xience V ® ), have recently become available in the USA and/or Europe. The Xience V stent holds the promise of superior anti-restenotic effi cacy as well as long-term safety. In addition, this stent is based on the Multi-link platform and delivery system. Recently available data already suggest the superiority of the Xience V stent in comparison to the Taxus stent in terms of prevention of restenosis, without signifi cant untoward events. Nonetheless, the number of patients studied and the follow-up duration are still too limited to enable defi nitive conclusions. Only indirect meta-analyses can be used to date to compare the Xience V with the Cypher. This systematic review tries to provide a concise and critical appraisal of the data in support of the Xience V everolimus-eluting stent.

show abstract

Compliance of a cobalt chromium coronary stent alloy – the COVIS trial

Cited by 19 publications

References 6 publications

Análise angiográfica e ultra-sonográfica do stent liberador de novolimus para o tratamento de lesões coronárias de novo: resultados do estudo EXCELLA I

Análise angiográfica e ultra-sonográfica do stent liberador de novolimus para o tratamento de lesões coronárias de novo: resultados do estudo EXCELLA I

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®)

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V<sup>®</sup>)

Contact Info

Product

Resources

About

Compliance of a cobalt chromium coronary stent alloy – the COVIS trial

Cited by 19 publications

References 6 publications

Análise angiográfica e ultra-sonográfica do stent liberador de novolimus para o tratamento de lesões coronárias de novo: resultados do estudo EXCELLA I

Análise angiográfica e ultra-sonográfica do stent liberador de novolimus para o tratamento de lesões coronárias de novo: resultados do estudo EXCELLA I

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®)

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V<sup>&reg;</sup>)

Contact Info

Product

Resources

About

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V<sup>®</sup>)